(Q39025406)

8 September 2017

1 reference

title

Role of gut microbiota in atherosclerosis (English)

1 reference

8 September 2017

1 reference

Fredrik Bäckhed

2

0 references

author name string

Annika Lindskog Jonsson

series ordinal

1

1 reference

PubMed ID

27905479

8 September 2017

language of work or name

English

0 references

publication date

1 December 2016

1 reference

Nature Reviews Cardiology

8 September 2017

1 reference

8 September 2017

14

1 reference

8 September 2017

2

1 reference

8 September 2017

79-87

1 reference

Structure, function and diversity of the healthy human microbiome

8 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

A human gut microbial gene catalogue established by metagenomic sequencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

An integrated catalog of reference genes in the human gut microbiome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

The gut microbiota--masters of host development and physiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Human oral, gut, and plaque microbiota in patients with atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

The relationship between periodontal disease (pd) and cardiovascular disease (cvd)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Association between dental health and acute myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Toothbrushing, inflammation, and risk of cardiovascular disease: results from Scottish Health Survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Oral microbiota in patients with atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Pathogen-mediated inflammatory atherosclerosis is mediated in part via Toll-like receptor 2-induced inflammatory responses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Porphyromonas gingivalis accelerates inflammatory atherosclerosis in the innominate artery of ApoE deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Aggregatibacter actinomycetemcomitans accelerates atherosclerosis with an increase in atherogenic factors in spontaneously hyperlipidemic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Symptomatic atherosclerosis is associated with an altered gut metagenome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Characterization of gut microbiota profiles in coronary artery disease patients using data mining analysis of terminal restriction fragment length polymorphism: gut microbiota could be a diagnostic marker of coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Analysis of Gut Microbiota in Coronary Artery Disease Patients: a Possible Link between Gut Microbiota and Coronary Artery Disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Chlamydia pneumoniae does not influence atherosclerotic plaque behavior in patients with established carotid artery stenosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Chlamydia pneumoniae DNA in non-coronary atherosclerotic plaques and circulating leukocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Increased CD8(+) T cells associated with Chlamydia pneumoniae in symptomatic carotid plaque

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

C-reactive protein levels and viable Chlamydia pneumoniae in carotid artery atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Microbial composition of atherosclerotic plaques

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

In silico analyses of metagenomes from human atherosclerotic plaque samples

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Risk of myocardial infarction and stroke after acute infection or vaccination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Chlamydia pneumoniae-Mediated Inflammation in Atherosclerosis: A Meta-Analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Cardiovascular disease after Escherichia coli O157:H7 gastroenteritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Antibiotic treatment of atherosclerotic cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Azithromycin for the secondary prevention of coronary events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Antibiotics in early life alter the murine colonic microbiome and adiposity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

The Levels of Inflammatory Markers in the Treatment of Stroke study (LIMITS): inflammatory biomarkers as risk predictors after lacunar stroke

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Insights into the role of infection in atherogenesis and in plaque rupture

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Pathogen recognition and innate immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Toll-like receptor signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Saturated fatty acids trigger TLR4-mediated inflammatory response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Crosstalk between Gut Microbiota and Dietary Lipids Aggravates WAT Inflammation through TLR Signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

TLR4 mutations are associated with endotoxin hyporesponsiveness in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Lack of association between TLR4 Asp299Gly polymorphism and atherosclerosis: evidence from meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

The gut microbiota as an environmental factor that regulates fat storage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Metabolic endotoxemia initiates obesity and insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Gut metagenome in European women with normal, impaired and diabetic glucose control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

The gut microbiota modulates host energy and lipid metabolism in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Role of bile acids and bile acid receptors in metabolic regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Microbiota-induced obesity requires farnesoid X receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

The farnesoid X-receptor is an essential regulator of cholesterol homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Antiatherosclerotic effect of farnesoid X receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Effects of FXR in foam-cell formation and atherosclerosis development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Expression and activation of the farnesoid X receptor in the vasculature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Diet-microbiota interactions as moderators of human metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Food, immunity, and the microbiome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

A high-fat diet is associated with endotoxemia that originates from the gut

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Metabonomic Changes Associated with Atherosclerosis Progression for LDLR(-/-) Mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Oral supplementation with non-absorbable antibiotics or curcumin attenuates western diet-induced atherosclerosis and glucose intolerance in LDLR-/- mice--role of intestinal permeability and macrophage activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Absence of microbiota (germ-free conditions) accelerates the atherosclerosis in ApoE-deficient mice fed standard low cholesterol diet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Infectious agents are not necessary for murine atherogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Responsiveness of cardiometabolic-related microbiota to diet is influenced by host genetics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Genetic and environmental control of host-gut microbiota interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

The Carnitine-butyrobetaine-trimethylamine-N-oxide pathway and its association with cardiovascular mortality in patients with carotid atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

The Relationship Between Trimethylamine-N-Oxide and Prevalent Cardiovascular Disease in a Multiethnic Population Living in Canada

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Genetic Architecture of Atherosclerosis in Mice: A Systems Genetics Analysis of Common Inbred Strains

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Transmission of atherosclerosis susceptibility with gut microbial transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

L-Carnitine intake and high trimethylamine N-oxide plasma levels correlate with low aortic lesions in ApoE(-/-) transgenic mice expressing CETP.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Trimethylamine N-Oxide Promotes Vascular Inflammation Through Signaling of Mitogen-Activated Protein Kinase and Nuclear Factor-κB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Fiber and prebiotics: mechanisms and health benefits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Whole-grain intake is inversely associated with the metabolic syndrome and mortality in older adults.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Inulin attenuates atherosclerosis in apolipoprotein E-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Probiotic therapy to men with incipient arteriosclerosis initiates increased bacterial diversity in colon: a randomized controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Effect of Lactobacillus reuteri on the prevention of hypercholesterolemia in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Effect of fermented milk containing Lactobacillus acidophilus and Bifidobacterium longum on plasma lipids of women with normal or moderately elevated cholesterol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Exopolysaccharide-producing probiotic Lactobacilli reduce serum cholesterol and modify enteric microbiota in ApoE-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Lactobacillus reuteri prevents diet-induced obesity, but not atherosclerosis, in a strain dependent fashion in Apoe-/- mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Effect of Lactobacillus delbrueckii on cholesterol metabolism in germ-free mice and on atherogenesis in apolipoprotein E knock-out mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

The Mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Akkermansia Muciniphila Protects Against Atherosclerosis by Preventing Metabolic Endotoxemia-Induced Inflammation in Apoe-/- Mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Infectious disease. Adapting Koch's postulates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.183

Infectious burden and carotid plaque thickness: the northern Manhattan study.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27905479

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27905479

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27905479

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCARDIO.2016.183

1 reference

8 September 2017

1 reference

PubMed ID

27905479